Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 37

1.

Chronic lymphocytic leukemia patients with heterogeneously or fully methylated LPL promotor display longer time to treatment.

Daugaard I, Hussmann D, Kristensen L, Kristensen T, Kjeldsen TE, Nyvold CG, Larsen TS, Møller MB, Hansen LL, Wojdacz TK.

Epigenomics. 2018 Sep;10(9):1155-1166. doi: 10.2217/epi-2018-0020. Epub 2018 Sep 5.

PMID:
30182737
2.

Differential expression levels and methylation status of ROBO1 in mantle cell lymphoma and chronic lymphocytic leukaemia.

Appe AJ, Aggerholm A, Hansen MC, Ebbesen LH, Hokland P, Bentzen HHN, Nyvold CG.

Int J Lab Hematol. 2017 Jun;39(3):e70-e73. doi: 10.1111/ijlh.12615. Epub 2016 Dec 22. No abstract available.

PMID:
28004534
3.

Novel scripts for improved annotation and selection of variants from whole exome sequencing in cancer research.

Hansen MC, Nederby L, Roug A, Villesen P, Kjeldsen E, Nyvold CG, Hokland P.

MethodsX. 2015 Mar 12;2:145-53. doi: 10.1016/j.mex.2015.03.003. eCollection 2015.

4.

Nature and nurture: a case of transcending haematological pre-malignancies in a pair of monozygotic twins adding possible clues on the pathogenesis of B-cell proliferations.

Hansen MC, Nyvold CG, Roug AS, Kjeldsen E, Villesen P, Nederby L, Hokland P.

Br J Haematol. 2015 May;169(3):391-400. doi: 10.1111/bjh.13305. Epub 2015 Mar 5.

PMID:
25752595
5.

Critical methodological factors in diagnosing minimal residual disease in hematological malignancies using quantitative PCR.

Nyvold CG.

Expert Rev Mol Diagn. 2015 May;15(5):581-4. doi: 10.1586/14737159.2015.1014341. Epub 2015 Feb 12.

PMID:
25676837
6.

SOX11, CCND1, BCL1/IgH and IgH-VDJ: a battle of minimal residual disease markers in mantle cell lymphoma?

Simonsen AT, Schou M, Sørensen CD, Bentzen HH, Nyvold CG.

Leuk Lymphoma. 2015;56(9):2724-7. doi: 10.3109/10428194.2015.1004672. Epub 2015 Feb 11. No abstract available.

PMID:
25629991
7.

Sensitive ligand-based protein quantification using immuno-PCR: A critical review of single-probe and proximity ligation assays.

Hansen MC, Nederby L, Henriksen MO, Hansen M, Nyvold CG.

Biotechniques. 2014 May;56(5):217-28.

PMID:
24919231
8.

Cell sorting enables interphase fluorescence in situ hybridization detection of low BCR-ABL1 producing stem cells in chronic myeloid leukaemia patients beyond deep molecular remission.

van Kooten Niekerk PB, Petersen CC, Nyvold CG, Ommen HB, Roug AS, Nederby L, Hokland P, Kjeldsen E.

Br J Haematol. 2014 Jan;164(1):53-60. doi: 10.1111/bjh.12589.

PMID:
24903628
9.

SOX11 as a minimal residual disease marker for Mantle cell lymphoma.

Simonsen AT, Sørensen CD, Ebbesen LH, Bødker JS, Bentzen HH, Nyvold CG.

Leuk Res. 2014 Aug;38(8):918-24. doi: 10.1016/j.leukres.2014.04.007. Epub 2014 Apr 28.

PMID:
24878000
10.

Common consensus LNA probe for quantitative PCR assays in cancer: vehicles for minimal residual disease detection in t(11;14) and t(14;18) positive malignant lymphomas.

Sørensen CD, Jørgensen JM, Nederby L, Hokland P, Nyvold CG.

J Immunol Methods. 2014 Apr;406:131-6. doi: 10.1016/j.jim.2014.03.004. Epub 2014 Mar 13.

PMID:
24631717
11.

Delineation of known and new transcript variants of the SETMAR (Metnase) gene and the expression profile in hematologic neoplasms.

Jeyaratnam DC, Baduin BS, Hansen MC, Hansen M, Jørgensen JM, Aggerholm A, Ommen HB, Hokland P, Nyvold CG.

Exp Hematol. 2014 Jun;42(6):448-56.e4. doi: 10.1016/j.exphem.2014.02.005. Epub 2014 Mar 4.

PMID:
24607956
12.

hMICL and CD123 in combination with a CD45/CD34/CD117 backbone - a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia.

Roug AS, Larsen HØ, Nederby L, Just T, Brown G, Nyvold CG, Ommen HB, Hokland P.

Br J Haematol. 2014 Jan;164(2):212-22. doi: 10.1111/bjh.12614. Epub 2013 Oct 24.

PMID:
24152218
13.

Mitochondrial cytochrome c oxidase subunit II variations predict adverse prognosis in cytogenetically normal acute myeloid leukaemia.

Silkjaer T, Nyvold CG, Juhl-Christensen C, Hokland P, Nørgaard JM.

Eur J Haematol. 2013 Oct;91(4):295-303. doi: 10.1111/ejh.12166. Epub 2013 Aug 20.

PMID:
23826975
14.

A novel RT-qPCR assay for quantification of the MLL-MLLT3 fusion transcript in acute myeloid leukaemia.

Abildgaard L, Ommen HB, Lausen B, Hasle H, Nyvold CG.

Eur J Haematol. 2013 Nov;91(5):394-8. doi: 10.1111/ejh.12156. Epub 2013 Oct 1.

PMID:
23772754
15.

Chronic myeloid leukaemia presenting with isolated thrombocythaemia, a case revealing its stem cell biology.

van Kooten Niekerk PB, Roug AS, Petersen CC, Ommen HB, Kjeldsen E, Bendix K, Nyvold CG, Nederby L, Hokland P.

Br J Haematol. 2013 Jul;162(1):141-4. doi: 10.1111/bjh.12339. Epub 2013 Apr 18. No abstract available.

PMID:
23593974
16.

Characterization and prognostic significance of mitochondrial DNA variations in acute myeloid leukemia.

Silkjaer T, Nørgaard JM, Aggerholm A, Ebbesen LH, Kjeldsen E, Hokland P, Nyvold CG.

Eur J Haematol. 2013 May;90(5):385-96. doi: 10.1111/ejh.12090. Epub 2013 Mar 22.

PMID:
23444869
17.

A highly sensitive and specific qPCR assay for quantification of the biomarker SOX11 in mantle cell lymphoma.

Hamborg KH, Bentzen HH, Grubach L, Hokland P, Nyvold CG.

Eur J Haematol. 2012 Nov;89(5):385-94. doi: 10.1111/j.1600-0609.2012.01837.x. Epub 2012 Aug 21. Review.

PMID:
22827557
18.

Sensitivity of minimal residual disease in acute myeloid leukaemia in first remission--methodologies in relation to their clinical situation.

Hokland P, Ommen HB, Nyvold CG, Roug AS.

Br J Haematol. 2012 Sep;158(5):569-80. doi: 10.1111/j.1365-2141.2012.09203.x. Epub 2012 Jun 28. Review.

PMID:
22738609
19.

Rapid detection of FLT3 exon 20 tyrosine kinase domain mutations in patients with acute myeloid leukemia by high-resolution melting analysis.

Tan AY, Wong SQ, Nyvold CG, Carney DA, Wei A, Seymour JF, Hokland P, Westerman, Dobrovic A.

Leuk Lymphoma. 2012 Jun;53(6):1225-9. doi: 10.3109/10428194.2011.645817. Epub 2012 Jan 13. No abstract available.

PMID:
22132874
20.

A patient with a 20-year lag phase between JAK2-V617F+ myeloproliferation and NPM1-mutated AML arguing against a common origin of disease.

Roug AS, Nyvold CG, Juhl-Christensen C, Christensen M, Schnittger S, Hokland P.

Eur J Haematol. 2011 Nov;87(5):461-3. doi: 10.1111/j.1600-0609.2011.01669.x. Epub 2011 Aug 11.

PMID:
21689158

Supplemental Content

Loading ...
Support Center